The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated miceEfforts to conduct additional preclinical studies, pursue optimized formulations and refine manufacturing processes are ongoing FORT LAUDERDALE, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT), an ea ...